Thomas Steyer’s Opus Genetics IRD Stock Holding History

Thomas Steyer’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000,000	Closed	-$4.55M	–	190
2026 Q1	$4.55M	Buy	+1,000,000	New	+$3.46M	0.02%	93

Other funds holding IRD

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Thomas Steyer's IRD Position: Q2 2026 in Review

Thomas Steyer sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 1,000,000 shares — an estimated $4.55M sold.

Thomas Steyer first reported a position in IRD in Q1 2026 and held it in 1 quarter. The position peaked at $4.55M in Q1 2026. 102 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

Thomas Steyer reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 1,000,000 Opus Genetics shares in Q2 2026, an estimated $4.55M.
Thomas Steyer first reported a position in Opus Genetics in Q1 2026 and held it in 1 quarter.
Thomas Steyer's Opus Genetics position peaked at $4.55M in Q1 2026.
102 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.